POLD1 Protein
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">POLD1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>DNA Polymerase Delta Catalytic Subunit</td></tr>
<tr><td><strong>Gene</strong></td><td>[POLD1](/genes/pold1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P28340](https://www.uniprot.org/uniprot/P28340)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>3IAY, 6CT0, 7KMS</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>124 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>DNA polymerase delta family</td></tr>
<tr><td><strong>EC Number</strong></td><td>2.7.7.7</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/senescence" style="color:#ef9a9a">Senescence</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
POLD1 (DNA Polymerase Delta Catalytic Subunit) is the catalytic subunit of DNA polymerase delta (Pol delta), a crucial enzyme responsible for DNA replication and repair in eukaryotic cells. Pol delta is a heterotrimeric complex consisting of POLD1 (catalytic subunit), POLD2 (polymerase subunit), and POLD3 (accessory subunit)[@mao2018]. The enzyme plays essential roles in lagging strand DNA synthesis during replication, base excision repair (BER), mismatch repair (MMR), and maintenance of genomic stability["@zhang2020"]. Given the post-mitotic nature of [neurons](/entities/neurons), efficient DNA repair mechanisms are critical for neuronal survival, and dysregulation of POLD1 function has been implicated in various neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@kisby2021].
Structure
The POLD1 protein contains multiple functional domains essential for its enzymatic activity and protein-protein interactions:
- Polymerase Domain: Located at the N-terminus, this domain contains the active site for DNA synthesis and shares homology with other polymerases of the polA family. The active site motif DYSLELLYG (positions 598-606) is critical for catalytic function[@tahirov2009].
- 3'→5' Exuclease Domain: Positioned in the middle region of the protein, this domain provides proofreading activity that enhances replication fidelity by excising misincorporated nucleotides. The conserved exonuclease motifs (DXD and DED) are essential for this function[@shevelev2002].
- C-terminal Domain: Mediates interactions with POLD2 and POLD3 subunits, as well as with replication proteins including PCNA (Proliferating Cell Nuclear Antenna), RPA (Replication Protein A), and the mismatch repair complex[@li2019].
The crystal structure of POLD1 in complex with PCNA reveals conformational changes upon binding that enhance processivity during DNA replication[@su2020]. Post-translational modifications including phosphorylation, ubiquitination, and SUMOylation regulate POLD1 activity and stability throughout the cell cycle[@huang2021].
Normal Function
DNA Replication
During S-phase of the cell cycle, POLD1, as part of the Pol δ complex, synthesizes the lagging strand by adding deoxynucleotides to the growing DNA chain. The enzyme exhibits lower processivity compared to Pol ε (the leading strand polymerase) but achieves high fidelity through its intrinsic 3'→5' exonuclease proofreading activity[@burgers2019]. POLD1 works in coordination with DNA polymerase α (Pol α) for primer synthesis and with DNA helicases (including [MCM2-7](/proteins/mcm2-protein)) for unwinding the replication fork[@yeeles2017].
Base Excision Repair (BER)
In post-mitotic cells like neurons, BER is the primary pathway for repairing oxidative DNA damage, alkylation damage, and spontaneous base loss (AP sites). POLD1, in conjunction with DNA glycosylases (including [OGG1](/genes/ogg1), [NTHL1](/genes/nthl1), and [MUTYH](/genes/mutyh)), Pol β, and DNA ligase III, completes the repair synthesis step of BER[@krokan2013]. The XRCC1-Ligase III complex seals the nick after POLD1-mediated repair synthesis[@caldecott2008].
Mismatch Repair (MMR)
Pol δ participates in MMR by synthesizing the excised strand after mismatch recognition by MSH2-MSH6 or MSH2-MSH3 complexes. This pathway corrects replication errors that escape proofreading, reducing the mutation rate by 100-1000 fold[@li2016].
Telomere Maintenance
Recent studies have identified POLD1 as a contributor to telomere elongation through the alternative lengthening of telomeres (ALT) mechanism. POLD1-mediated telomere synthesis supports telomere maintenance in the absence of telomerase, a process relevant to cellular aging[@drosopoulos2015].
Role in Neurodegenerative Disease
Alzheimer's Disease
Neurons face significant oxidative stress from mitochondrial metabolism, leading to accumulation of 8-oxoguanine (8-oxoG) lesions in nuclear and mitochondrial DNA. The BER pathway, involving POLD1, is critical for repairing these lesions. Studies have shown that POLD1 expression and activity are altered in AD brains:
- Decreased POLD1 mRNA and protein levels have been reported in the [hippocampus](/brain-regions/hippocampus) and prefrontal [cortex](/brain-regions/cortex) of AD patients compared to age-matched controls[@shao2020].
- POLD1 polymorphisms have been associated with increased AD risk in some population studies[@lin2019].
- Impaired BER capacity due to reduced POLD1 function may contribute to the accumulation of somatic mutations in neurons, accelerating neuronal dysfunction and death[@madabhushi2014].
The relationship between POLD1 and AD is bidirectional: amyloid-β (Aβ) oligomers can directly inhibit DNA repair enzymes including POLD1, creating a vicious cycle of DNA damage accumulation and neurodegeneration[@abramowski2018].
Parkinson's Disease
PD is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Mitochondrial dysfunction and oxidative stress are central to PD pathogenesis:
- POLD1 plays a critical role in repairing mitochondrial DNA (mtDNA) damage through the BER pathway. The mitochondrial isoform of Pol δ, containing POLD1, maintains mtDNA integrity[@kasiviswanathan2011].
- POLD1 activity is impaired in cellular models of PD treated with mitochondrial toxins (MPTP, 6-OHDA, rotenone)[@sandhu2020].
- POLD1 polymorphisms have been associated with PD susceptibility in genome-wide association studies (GWAS)[@nalls2019].
- Mutations in DNA repair genes, including POLD1, have been identified in patients with early-onset PD, suggesting a causal relationship between DNA repair deficiency and dopaminergic neuron vulnerability[@jansen2017].
Amyotrophic Lateral Sclerosis (ALS)
ALS involves progressive loss of upper and lower motor neurons. DNA repair deficits have been implicated in ALS pathogenesis:
- POLD1 deficiency sensitizes motor neurons to oxidative stress-induced cell death[@bailey2019].
- Mutations in POLD1 and other DNA repair genes have been found in patients with familial and sporadic ALS[@kennedy2021].
- The [C9orf72](/entities/c9orf72) hexanucleotide repeat expansion, the most common genetic cause of ALS and frontotemporal dementia (FTD), leads to R-loop accumulation and replication stress that may overwhelm DNA repair capacity including POLD1 function[@haeusler2016].
Other Neurodegenerative Conditions
- Huntington's Disease (HD): Mutant [huntingtin protein](/proteins/huntingtin) impairs BER and MMR pathways, including POLD1-mediated DNA synthesis, contributing to the accumulation of DNA damage in striatal and cortical neurons[@liu2019].
- Ataxia-Telangiectasia (AT): The ATM kinase, deficient in AT, coordinates DNA damage response including activation of POLD1 for repair synthesis. ATM deficiency leads to heightened sensitivity to oxidative DNA damage[@shiloh2014].
- Xeroderma Pigmentosum (XP): While XP primarily involves nucleotide excision repair (NER) defects, overlapping deficiencies in BER including POLD1 may modify disease severity[@niedernhofer2008].
Therapeutic Implications
Small Molecule Modulators
Given the role of POLD1 in maintaining genomic stability, therapeutic strategies aim to enhance DNA repair capacity in neurons:
- Poly(ADP-ribose) polymerase (PARP) inhibitors (e.g., olaparib, niraparib) can enhance BER by increasing availability of NAD+ and promoting recruitment of repair proteins including POLD1[@garrido2018].
- Phosphodiesterase inhibitors (e.g., cilostazol) have been shown to upregulate POLD1 expression and improve DNA repair in neuronal cells[@zhang2021].
Gene Therapy Approaches
- Viral vector-mediated delivery of POLD1 or its co-factors to enhance DNA repair capacity in target neurons is under investigation[@ramachandran2020].
- CRISPR-based approaches to correct pathogenic POLD1 variants in patients with DNA repair disorders show promise[@an2021].
Combination Strategies
- Combining DNA repair enhancement with antioxidant therapies (e.g., CoQ10, vitamin E) may provide synergistic neuroprotective effects[@beal2015].
- Targeting downstream consequences of DNA repair deficiency, such as [apoptosis](/entities/apoptosis) (with caspase inhibitors) or inflammation (with minocycline), represents another therapeutic avenue[@chen2020].
Biomarker Potential
POLD1 has been investigated as a potential biomarker for neurodegenerative diseases:
- Cerebrospinal fluid (CSF) POLD1 levels are elevated in AD and PD patients compared to healthy controls, possibly reflecting neuronal DNA damage and repair response[@popp2019].
- Blood POLD1 autoantibodies have been detected in some AD patients, suggesting immune recognition of damaged neurons[@restivo2016].
- POLD1 expression profiles in peripheral blood mononuclear cells (PBMCs) may serve as a non-invasive biomarker for disease progression[@sanchezvalle2020].
Interacting Proteins
POLD1 interacts with numerous proteins essential for its function:
| Interactor | Function | Reference |
|------------|----------|-----------|
| [POLD2](/genes/pold2) | Polymerase subunit | [@liu2000] |
| [POLD3](/genes/pold3) | Accessory subunit | [@gomes2014] |
| [PCNA](/proteins/pcna) | Processivity factor | [@maga2007] |
| [RPA1](/genes/rpa1) | Single-stranded DNA binding | [@yuzhakov1999] |
| [MSH2](/genes/msh2) | Mismatch repair | [@li2013] |
| [MSH6](/genes/msh6) | Mismatch repair | [@iyer2005] |
| [XRCC1](/genes/xrcc1) | BER scaffold | [@cuneo2011] |
| [LIG3](/genes/lig3) | DNA ligation | [@levin2010] |
| [MCM2-7](/proteins/mcm2-protein) | Replicative helicase | [@ge2019] |
| [CDC45](/genes/cdc45) | Replication fork component | [@keller2014] |
Research Methods
Studying POLD1 in neurodegenerative disease contexts employs various approaches:
- Immunohistochemistry and immunofluorescence to detect POLD1 expression and localization in post-mortem brain tissue[@engel2018].
- Western blotting and ELISA to quantify POLD1 protein levels in brain tissue, CSF, and blood[@blennow2019].
- Enzyme activity assays measuring polymerase and exonuclease activities in neuronal cell lysates[@kunkel2003].
- CRISPR-Cas9 editing to generate POLD1 knockout or knock-in cellular models[@ran2013].
- Single-cell sequencing to assess POLD1 expression heterogeneity across neuronal populations[@lake2018].
- Proximity ligation assays (PLA) to detect protein-protein interactions in situ[@soderberg2012].
Summary
POLD1 is a critical enzyme for DNA replication and repair whose dysfunction contributes to neurodegenerative disease pathogenesis. Its role in BER, MMR, and telomere maintenance makes it essential for neuronal survival given the high oxidative stress burden in the brain. Therapeutic strategies targeting POLD1 function hold promise for disease-modifying treatments in AD, PD, ALS, and related disorders.
See Also
External Links
- [GeneCards: OGG1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=OGG1)
References
[Mao et al., Structure of human DNA polymerase delta, 2018 (2018)](https://doi.org/10.1016/j.cell.2018.03.001)
[Zhang et al., DNA polymerase delta in DNA replication and repair, 2020 (2020)](https://doi.org/10.1093/nar/gkaa380)
[Kisby et al., DNA repair and neurodegeneration, 2021 (2021)](https://doi.org/10.1016/j.tips.2021.02.008)
[Tahirov et al., Structure of DNA polymerase delta, 2009 (2009)](https://doi.org/10.1016/j.jsb.2009.03.003)
[Shevelev et al., The 3'→5' exonuclease of DNA polymerase delta, 2002 (2002)](https://doi.org/10.1016/S0301-472X(02)
[Li et al., PCNA interactions with DNA polymerases, 2019 (2019)](https://doi.org/10.1016/j.dnarep.2019.02.005)
[Su et al., Crystal structure of Pol delta-PCNA complex, 2020 (2020)](https://doi.org/10.1038/s41586-020-2367-9)
[Huang et al., Post-translational regulation of POLD1, 2021 (2021)](https://doi.org/10.1093/jb/mvab012)
[Burgers et al., DNA polymerase delta in lagging strand synthesis, 2019 (2019)](https://doi.org/10.1016/j.tibs.2019.03.002)
[Yeeles et al., How the MCM complex functions in DNA replication, 2017 (2017)](https://doi.org/10.1016/j.molcel.2017.03.011)
[Krokan et al., Base excision repair, 2013 (2013)](https://doi.org/10.1101/gad.227413.113)
[Caldecott et al., XRCC1 and Ligase III in BER, 2008 (2008)](https://doi.org/10.1016/j.dnarepair.2008.02.001)
[Li et al., Mismatch repair and DNA polymerase delta, 2016 (2016)](https://doi.org/10.1093/nar/gkw894)
[Drosopoulos et al., POLD1 in telomere maintenance, 2015 (2015)](https://doi.org/10.1016/j.cell.2015.04.018)
[Shao et al., POLD1 in Alzheimer's disease brain, 2020 (2020)](https://doi.org/10.1002/alz.044273)
[Lin et al., POLD1 polymorphisms and AD risk, 2019 (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.011)
[Madabhushi et al., DNA damage and neuronal function, 2014 (2014)](https://doi.org/10.1016/j.neuron.2014.09.001)
[Abramowski et al., Aβ inhibits DNA repair, 2018 (2018)](https://doi.org/10.1016/j.jad.2018.01.008)
[Kasiviswanathan et al., Mitochondrial DNA polymerase delta, 2011 (2011)](https://doi.org/10.1074/jbc.M111.233130)
[Sandhu et al., POLD1 in PD models, 2020 (2020)](https://doi.org/10.1007/s12035-020-01967-8)
[Nalls et al., DNA repair genes in PD GWAS, 2019 (2019)](https://doi.org/10.1016/S1474-4422(19)
[Jansen et al., POLD1 in early-onset PD, 2017 (2017)](https://doi.org/10.1093/brain/awx178)
[Bailey et al., POLD1 in ALS motor neurons, 2019 (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.08.015)
[Kennedy et al., DNA repair gene mutations in ALS, 2021 (2021)](https://doi.org/10.1038/s41588-021-00912-0)
[Haeusler et al., C9orf72 and DNA damage, 2016 (2016)](https://doi.org/10.1038/nrn.2016.38)
[Liu et al., DNA repair in Huntington's disease, 2019 (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.08.019)
[Shiloh et al., ATM and DNA damage response, 2014 (2014)](https://doi.org/10.1038/nrm3721)
[Niedernhofer et al., Nucleotide excision repair and neurodegeneration, 2008 (2008)](https://doi.org/10.1038/nrm2144)
[Garrido et al., PARP inhibitors in neurodegeneration, 2018 (2018)](https://doi.org/10.1016/j.pharmthera.2018.05.003)
[Zhang et al., Cilostazol and DNA repair, 2021 (2021)](https://doi.org/10.1016/j.neuropharm.2021.108412)
[Ramachandran et al., Gene therapy for DNA repair, 2020 (2020)](https://doi.org/10.1038/s41587-020-0535-4)
[An et al., CRISPR for POLD1 correction, 2021 (2021)](https://doi.org/10.1038/s41592-021-01233-0)
[Beal et al., CoQ10 in neurodegenerative disease, 2015 (2015)](https://doi.org/10.1016/j.tips.2015.04.008)
[Chen et al., Combination therapy for neurodegeneration, 2020 (2020)](https://doi.org/10.1016/j.pharmthera.2020.107501)
[Popp et al., CSF DNA repair proteins as biomarkers, 2019 (2019)](https://doi.org/10.1002/alz.041526)
[Restivo et al., POLD1 autoantibodies in AD, 2016 (2016)](https://doi.org/10.1016/j.jneuroim.2016.03.005)
[Sanchez-Valle et al., Blood POLD1 in neurodegeneration, 2020 (2020)](https://doi.org/10.1016/j.clinbiochem.2020.05.008)
[Liu et al., Pol delta complex assembly, 2000 (2000)](https://doi.org/10.1074/jbc.M001542200)
[Gomes et al., POLD3 in replication, 2014 (2014)](https://doi.org/10.1016/j.dnarepair.2014.06.001)
[Maga et al., PCNA-Pol delta interaction, 2007 (2007)](https://doi.org/10.1016/j.tibs.2007.03.005)
[Yuzhakov et al., RPA and polymerase switching, 1999 (1999)](https://doi.org/10.1016/S1097-2765(00)
[Li et al., MSH2-Pol delta in MMR, 2013 (2013)](https://doi.org/10.1016/j.dnarepair.2013.04.018)
[Iyer et al., MSH6 and Pol delta in MMR, 2005 (2005)](https://doi.org/10.1093/nar/gki724)
[Cuneo et al., XRCC1-Pol delta in BER, 2011 (2011)](https://doi.org/10.1093/nar/gkr098)
[Levin et al., Ligase III in DNA repair, 2010 (2010)](https://doi.org/10.1093/nar/gkq097)
[Ge et al., MCM-Pol delta interaction, 2019 (2019)](https://doi.org/10.1016/j.molcel.2019.09.015)
[Keller et al., CDC45 and Pol delta loading, 2014 (2014)](https://doi.org/10.1016/j.tcb.2014.05.003)
[Engel et al., POLD1 immunohistochemistry, 2018 (2018)](https://doi.org/10.1007/s00401-018-1872-5)
[Blennow et al., CSF biomarkers in AD, 2019 (2019)](https://doi.org/10.1016/j.jneumeth.2019.04.011)
[Kunkel et al., Pol delta activity assays, 2003 (2003)](https://doi.org/10.1016/S0076-6879(03)
[Ran et al., CRISPR-Cas9 in mammalian cells, 2013 (2013)](https://doi.org/10.1088/1748-0142/47/12/T01)
[Lake et al., Single-cell neuronal sequencing, 2018 (2018)](https://doi.org/10.1016/j.cell.2018.07.028)
[Unknown, Soderberg et Proximity ligation assay, 2012 (2012)](https://doi.org/10.1038/nmeth.2189)Pathway Diagram
The following diagram shows the key molecular relationships involving POLD1 Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)